Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Raises $11M in Follow-on Financing

NEW YORK (GenomeWeb) – Biodesix today announced that it has raised $11 million in a private follow-on sale. 

The amount is in addition to $27 million that the firm raised in sales of its Series E preferred shares starting in 2013, bringing the total proceeds to $38 million. Existing Biodesix shareholders invested in the new round, the company said. 

The financing will be used for new product development and to expand the commercialization of the VeriStrat and GeneStrat tests, as well as new product launches this year and in 2016. 

VeriStrat is a blood-based serum protein test for non-small cell lung cancer. Aetna issued a positive coverage decision for the test earlier this month. GeneStrat is a targeted blood-based mutation test for patients with advanced cancer.